# TARE / SIRT (radioembolisation with yttrium-90)

Source: https://nuclide.cc/terms/tare/  
Nuclide record `tare` (Term). Data CC BY-NC 4.0, attribute "Data from Nuclide (nuclide.cc)"; commercial use needs a licence.

## TL;DR

Injecting tiny radioactive glass or resin beads into the liver's artery so they lodge in the tumour and irradiate it from inside.

## Summary

Yttrium-90 microspheres (20-60 µm) deliver beta radiation over a few millimetres with a 64-hour half-life, treating hepatocellular carcinoma, colorectal liver metastases and neuroendocrine liver metastases. Randomised trials against sorafenib (SARAH, SIRveNIB) showed no survival gain but better tolerability; radiation segmentectomy, which delivers ablative doses to a small segment, achieves outcomes close to ablation. Dosimetry now individualises the activity (DOSISPHERE). Chosen over TACE when portal vein thrombus is present.

## Fields

- Kind: Term
- Last checked: 2026-09-09
- Also known as: TARE; SIRT; radioembolisation; radioembolization; Y-90; Y90; yttrium-90; selective internal radiation therapy; 90Y microspheres

## Sources

- Wikipedia: https://en.wikipedia.org/wiki/Selective_internal_radiation_therapy
- Wikipedia: https://en.wikipedia.org/wiki/Selective_internal_radiation_therapy

## Connected records

- isotopes: [Yttrium-90](https://nuclide.cc/isotopes/y-90/)
- indications: [Hepatocellular carcinoma](https://nuclide.cc/indications/hcc/), [Neuroendocrine tumours](https://nuclide.cc/indications/neuroendocrine/)
- companies: [Quirem Medical](https://nuclide.cc/companies/quirem-medical/)
- fronts: [Radioembolisation](https://nuclide.cc/fronts/f-radioembolisation/)

---
JSON: https://nuclide.cc/api/v1/entities/tare.json